PLX122876
GSE113031: The IMiDs, through loss of Ikaros and Aiolos, primes myeloma cells for daratumumab mediated killing by upregulation of CD38
- Organsim human
- Type RNASEQ
- Target gene
- Project ARCHS4
Recent studies have demonstrated that the immunomodulatory drugs (IMiDs) lead to the degradation of the transcription factors Ikaros and Aiolos. However, why their loss subsequently leads to multiple myeloma (MM) cell death remains unclear. Using CRISPR-Cas9 genome editing, we have deleted IKZF1 and IKZF3 in human MM cell lines to gain further insight into their downstream gene regulatory networks. Our findings strongly support the central role of Ikaros and Aiolos in the action of the IMiDs. Inactivation of either factor alone recapitulates the cell intrinsic action of the IMiDs, resulting in cell cycle arrest and induction of apoptosis. Furthermore, evaluation of the transcriptional changes resulting from their loss demonstrates striking overlap with lenalidomide treatment. SOURCE: Wei Shi (shi@wehi.edu.au) - The Walter and Eliza Hall Institute of Medical Research
View on GEOView in PlutoKey Features
Enhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn MoreAnalyze and visualize data for this experiment
Use Pluto's intuitive interface to analyze and visualize data for this experiment. Pluto's platform is equipped with an API & SDKs, making it easy to integrate into your internal bioinformatics processes.
Read about post-pipeline analysisView QC data and experiment metadata
View quality control data and experiment metadata for this experiment.
Request import of other GEO data
Request imports from GEO or TCGA directly within Pluto Bio.
Chat with our Scientific Insights team